- Home
- CRVS vs CION Comparison
CRVS vs CION Comparison
Compare CRVS & CION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- CION
- Stock Information
- Founded
- CRVS 2014
- CION 2011
- Country
- CRVS United States
- CION United States
- Employees
- CRVS N/A
- CION N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- CION Finance/Investors Services
- Sector
- CRVS Health Care
- CION Finance
- Exchange
- CRVS Nasdaq
- CION Nasdaq
- Market Cap
- CRVS 459.0M
- CION 504.8M
- IPO Year
- CRVS 2016
- CION N/A
- Fundamental
- Price
- CRVS $8.79
- CION $9.91
- Analyst Decision
- CRVS Strong Buy
- CION Sell
- Analyst Count
- CRVS 4
- CION 1
- Target Price
- CRVS $13.75
- CION $8.50
- AVG Volume (30 Days)
- CRVS 1.0M
- CION 299.9K
- Earning Date
- CRVS 11-04-2025
- CION 11-06-2025
- Dividend Yield
- CRVS N/A
- CION 15.01%
- EPS Growth
- CRVS N/A
- CION N/A
- EPS
- CRVS N/A
- CION 0.49
- Revenue
- CRVS N/A
- CION $244,923,000.00
- Revenue This Year
- CRVS N/A
- CION N/A
- Revenue Next Year
- CRVS N/A
- CION N/A
- P/E Ratio
- CRVS N/A
- CION $20.19
- Revenue Growth
- CRVS N/A
- CION N/A
- 52 Week Low
- CRVS $2.54
- CION $8.51
- 52 Week High
- CRVS $9.55
- CION $12.71
- Technical
- Relative Strength Index (RSI)
- CRVS 63.66
- CION 58.50
- Support Level
- CRVS $8.34
- CION $9.70
- Resistance Level
- CRVS $9.22
- CION $9.97
- Average True Range (ATR)
- CRVS 0.55
- CION 0.25
- MACD
- CRVS 0.01
- CION 0.02
- Stochastic Oscillator
- CRVS 83.41
- CION 59.09
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About CION CION Investment Corporation
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.